119 related articles for article (PubMed ID: 36639281)
1. Epidemiological and Therapeutic Analyses in Lung Cancer Patients Over 80 Years Old in the Hokushin Region: A Retrospective Hospital Administrative Database Study.
Koizumi T; Nishino Y; Takiguchi T; Kanda S; Otsuki K; Tanaka Y; Tomita R; Araki T; Hayashi R; Yasumoto K; Uramoto H; Hirono Y; Makino T; Nakada M; Yano S
Clin Lung Cancer; 2023 Mar; 24(2):145-152. PubMed ID: 36639281
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study.
Kobayashi T; Nishino Y; Takiguchi T; Kanda S; Otsuki K; Tanaka Y; Nakazawa Y; Ito KI; Hayashi R; Yasumoto K; Uramoto H; Hirono Y; Makino T; Nakada M; Yano S; Koizumi T
BMC Pulm Med; 2023 Sep; 23(1):322. PubMed ID: 37658334
[TBL] [Abstract][Full Text] [Related]
3. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
5. What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.
Lester JF; Agulnik J; Akerborg O; Chouaid C; De Geer A; Finnern HW; Herder GJ; Lungershausen J; Mitchell PL; Vansteenkiste J; Ziske C; Goker E
Lung Cancer; 2013 Oct; 82(1):128-35. PubMed ID: 23910909
[TBL] [Abstract][Full Text] [Related]
6. A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients.
Sekine I; Shintani Y; Shukuya T; Takayama K; Inoue A; Okamoto I; Kiura K; Takahashi K; Dosaka-Akita H; Takiguchi Y; Miyaoka E; Okumura M; Yoshino I
Cancer Sci; 2020 May; 111(5):1685-1691. PubMed ID: 32103551
[TBL] [Abstract][Full Text] [Related]
7. Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients.
Aoki T; Akiba T; Nishiyama J; Tajiri S; Hayama N; Takahashi G; Tanaka J; Sato M; Takiguchi H; Tomomatsu H; Tomomatsu K; Takihara T; Niimi K; Oguma T; Kohno M; Masuda R; Urano T; Itoh H; Kajiwara H; Nakamura N; Kunieda E; Matsumae M; Iwazaki M; Asano K
Respir Res; 2019 Nov; 20(1):263. PubMed ID: 31752884
[TBL] [Abstract][Full Text] [Related]
8. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
Ikeda S; Yoshioka H; Ikeo S; Morita M; Sone N; Niwa T; Nishiyama A; Yokoyama T; Sekine A; Ogura T; Ishida T
BMC Cancer; 2017 Nov; 17(1):797. PubMed ID: 29183294
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
10. Non-small Cell Lung Cancer (NSCLC) in Octogenarians in Clinical Practice.
Koyi H; Hillerdal G; Kölbeck KG; Brodin D; Liv P; Brandén E
Anticancer Res; 2016 Oct; 36(10):5397-5402. PubMed ID: 27798905
[TBL] [Abstract][Full Text] [Related]
11. Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74 years and 75 years or older.
Driessen E; Detillon D; Bootsma G; De Ruysscher D; Veen E; Aarts M; Janssen-Heijnen M
J Geriatr Oncol; 2019 Jul; 10(4):547-554. PubMed ID: 30876833
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.
Evers J; de Jaeger K; Hendriks LEL; van der Sangen M; Terhaard C; Siesling S; De Ruysscher D; Struikmans H; Aarts MJ
Lung Cancer; 2021 May; 155():103-113. PubMed ID: 33774382
[TBL] [Abstract][Full Text] [Related]
15. Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
J Cancer Res Clin Oncol; 2021 Jan; 147(1):287-293. PubMed ID: 32761377
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer outcomes at a UK cancer unit between 1998-2001.
Free CM; Ellis M; Beggs L; Beggs D; Morgan SA; Baldwin DR
Lung Cancer; 2007 Aug; 57(2):222-8. PubMed ID: 17442450
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
[TBL] [Abstract][Full Text] [Related]
18. Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.
Deepak JA; Ng X; Feliciano J; Mao L; Davidoff AJ
Ann Am Thorac Soc; 2015 May; 12(5):742-51. PubMed ID: 25760983
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
